While new interferon-free direct-acting antiviral therapy can cure more than 90% of people with chronic hepatitis C -- including those with HIV/HCV coinfection -- access to treatment remains a major challenge, experts said at a media briefing on HIV and hepatitis coinfection at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention last month in Vancouver.
[Tracy Swan, IAS 2015, July 22, 2015]
"Just from an investment perspective, it makes perfect sense to make [hepatitis C] treatment available to all HIV-positive people who are coinfected with hepatitis C," said Tracy Swan of the Treatment Action Group.
Swan also stressed the importance of global availability of direct-acting antivirals for hepatitis C that can be safely used with widely used antiretrovirals for HIV.
8/19/15
Source
8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention. Media briefing, July 22, 2015.